The offering will dilute existing shareholders by roughly 10%, likely pressuring the stock near term. Monitor the stock's reaction at the open; the $20.50 offering price may act as a near-term floor. Proceeds extend the cash runway for DMD and DM1 clinical programs, reducing near-term financing risk.
Price Chart
Executive Summary
Dyne Therapeutics priced an upsized underwritten public offering of 18.3 million shares at $20.50 per share, raising gross proceeds of $375.15 million. The offering will dilute existing shareholders by approximately 9-11% (including the underwriter option) and provides additional cash runway for the company's clinical-stage neuromuscular programs.
Key Financial Metrics
Key Facts
- Offering of 18,300,000 shares at $20.50 per share, upsized from original terms.
- Gross proceeds expected to be $375,150,000 before expenses.
- Underwriters have a 30-day option to purchase up to an additional 2,745,000 shares.
- Expected to close on or about July 23, 2026.
- Joint book-running managers: Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, Raymond James.
Financial Impact
Gross proceeds of $375.15 million from the sale of 18.3 million shares (plus up to 2.745 million additional shares via underwriter option). Dilution to existing shareholders is significant given the company's pre-revenue status.
Risk Factors
- Significant dilution to existing shareholders (approximately 9.6% base, up to 11% with overallotment).
- Potential downward pressure on stock price as new shares enter the market.
- Clinical-stage company with no approved products; offering proceeds may be consumed before reaching key milestones.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3331062 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 17, 2026 6w ago | Insider Cluster | $26.15 $17.90 | ▲ +31.55% | ▲ +29.57% | $15.20 (+41.87%) |
Aug 14, 2026 6w ago | 144 | $26.15 $18.52 | ▼ −29.18% | ▼ −27.65% | $15.20 (−41.87%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▲ +27.94% | ▲ +25.95% | $15.20 (+40.86%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▼ −27.94% | ▼ −25.95% | $15.20 (−40.86%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▼ −27.94% | ▼ −25.95% | $15.20 (−40.86%) |
Jul 29, 2026 9w ago | Press Release | $25.73 $26.09 | ▲ +1.40% | ▼ −2.57% | $15.20 (−40.92%) |
Jul 22, 2026 10w ago | Press Release | $23.21 $26.78 | ▼ −15.38% | ▼ −12.48% | $15.20 (+34.51%) |
Jul 20, 2026 10w ago | 8-K | $23.45 $26.15 | ▲ +11.51% | ▲ +7.39% | $15.20 (−35.18%) |
Jun 30, 2026 13w ago | Insider Cluster | $21.79 $25.10 | ▲ +15.19% | ▲ +17.38% | $15.20 (−30.24%) |
Jun 29, 2026 13w ago | 144 | $22.21 $25.63 | ▼ −15.40% | ▼ −16.43% | $15.20 (+31.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access